LivaNova PLC (NASDAQ:LIVN) Shares Sold by Headlands Technologies LLC

Headlands Technologies LLC trimmed its holdings in LivaNova PLC (NASDAQ:LIVN) by 39.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,971 shares of the company’s stock after selling 8,331 shares during the quarter. Headlands Technologies LLC’s holdings in LivaNova were worth $601,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Nordea Investment Management AB increased its stake in LivaNova by 22.2% in the fourth quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after purchasing an additional 12,470 shares during the period. Harbor Capital Advisors Inc. acquired a new position in LivaNova in the 4th quarter valued at about $1,954,000. KBC Group NV raised its stake in LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company’s stock valued at $4,628,000 after acquiring an additional 56,580 shares during the last quarter. Rhumbline Advisers lifted its position in LivaNova by 0.5% during the 4th quarter. Rhumbline Advisers now owns 177,938 shares of the company’s stock worth $8,240,000 after acquiring an additional 899 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in shares of LivaNova by 29.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 6,311 shares of the company’s stock valued at $292,000 after purchasing an additional 1,424 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

LIVN has been the topic of a number of analyst reports. Stifel Nicolaus lowered their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Wolfe Research cut shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. The Goldman Sachs Group reduced their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Barclays dropped their target price on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Finally, StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 25th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $61.17.

LivaNova Stock Performance

LIVN opened at $39.50 on Thursday. The stock’s 50 day simple moving average is $43.94 and its 200 day simple moving average is $48.29. The stock has a market cap of $2.15 billion, a P/E ratio of 94.05 and a beta of 1.10. LivaNova PLC has a 1-year low of $36.85 and a 1-year high of $64.48. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.